01 1Cambridge Isotope Laboratories, Inc.
02 1Sigma-Aldrich Corporation
01 1UREA C-13
02 1Urea-13C
01 2U.S.A
NDC Package Code : 61444-901
Start Marketing Date : 1996-02-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 17445-6034
Start Marketing Date : 1995-01-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1800g/1800g)
Marketing Category : BULK INGREDIENT
A UREA C-13 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of UREA C-13, including repackagers and relabelers. The FDA regulates UREA C-13 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. UREA C-13 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A UREA C-13 supplier is an individual or a company that provides UREA C-13 active pharmaceutical ingredient (API) or UREA C-13 finished formulations upon request. The UREA C-13 suppliers may include UREA C-13 API manufacturers, exporters, distributors and traders.
click here to find a list of UREA C-13 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing UREA C-13 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for UREA C-13 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture UREA C-13 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain UREA C-13 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a UREA C-13 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of UREA C-13 suppliers with NDC on PharmaCompass.
We have 2 companies offering UREA C-13
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
